Free Trial

Organigram (OGI) Competitors

$1.71
0.00 (0.00%)
(As of 05/31/2024 ET)

OGI vs. PAHC, STOK, NRIX, AUPH, TNGX, LBPH, GHRS, SAGE, LYEL, and ALXO

Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Phibro Animal Health (PAHC), Stoke Therapeutics (STOK), Nurix Therapeutics (NRIX), Aurinia Pharmaceuticals (AUPH), Tango Therapeutics (TNGX), Longboard Pharmaceuticals (LBPH), GH Research (GHRS), Sage Therapeutics (SAGE), Lyell Immunopharma (LYEL), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical preparations" industry.

Organigram vs.

Phibro Animal Health (NASDAQ:PAHC) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment.

Phibro Animal Health has a net margin of 1.32% compared to Phibro Animal Health's net margin of -188.38%. Organigram's return on equity of 17.11% beat Phibro Animal Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Phibro Animal Health1.32% 17.11% 4.83%
Organigram -188.38%-40.19%-34.70%

Phibro Animal Health has higher revenue and earnings than Organigram. Organigram is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phibro Animal Health$977.90M0.73$32.61M$0.3255.10
Organigram$120.01M1.47-$184.34M-$0.94-1.82

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 34.6% of Organigram shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 0.1% of Organigram shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Phibro Animal Health has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Organigram has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

In the previous week, Phibro Animal Health had 1 more articles in the media than Organigram. MarketBeat recorded 3 mentions for Phibro Animal Health and 2 mentions for Organigram. Phibro Animal Health's average media sentiment score of 0.93 beat Organigram's score of 0.56 indicating that Organigram is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Phibro Animal Health
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Organigram
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Phibro Animal Health currently has a consensus price target of $14.75, indicating a potential downside of 16.34%. Given Organigram's higher possible upside, equities research analysts plainly believe Phibro Animal Health is more favorable than Organigram.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phibro Animal Health
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75
Organigram
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Phibro Animal Health received 108 more outperform votes than Organigram when rated by MarketBeat users. However, 70.61% of users gave Organigram an outperform vote while only 59.92% of users gave Phibro Animal Health an outperform vote.

CompanyUnderperformOutperform
Phibro Animal HealthOutperform Votes
305
59.92%
Underperform Votes
204
40.08%
OrganigramOutperform Votes
197
70.61%
Underperform Votes
82
29.39%

Summary

Phibro Animal Health beats Organigram on 12 of the 17 factors compared between the two stocks.

Get Organigram News Delivered to You Automatically

Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OGI vs. The Competition

MetricOrganigramPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$176.76M$6.73B$5.13B$7.96B
Dividend YieldN/A2.68%2.75%4.01%
P/E Ratio-1.8222.62167.0318.57
Price / Sales1.47394.412,422.3491.69
Price / CashN/A32.8835.2531.51
Price / Book0.886.085.534.59
Net Income-$184.34M$138.60M$106.01M$213.90M
7 Day Performance-6.04%3.29%1.14%0.87%
1 Month Performance-10.70%1.09%1.43%3.60%
1 Year Performance9.62%-1.29%4.07%7.91%

Organigram Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PAHC
Phibro Animal Health
3.5381 of 5 stars
$18.55
+0.5%
$14.75
-20.5%
+36.5%$751.28M$977.90M57.971,920
STOK
Stoke Therapeutics
4.2573 of 5 stars
$14.41
-2.0%
$20.57
+42.8%
+29.5%$751.05M$8.78M-5.98110Analyst Revision
NRIX
Nurix Therapeutics
1.6602 of 5 stars
$15.17
flat
$21.88
+44.2%
+54.9%$745.61M$76.99M-5.70284
AUPH
Aurinia Pharmaceuticals
1.7168 of 5 stars
$5.21
-0.6%
$10.00
+91.9%
-40.6%$743.26M$175.51M-12.12300Short Interest ↑
TNGX
Tango Therapeutics
2.4236 of 5 stars
$6.91
-2.5%
$14.83
+114.7%
+159.2%$738.33M$36.53M-6.12140Analyst Forecast
Analyst Revision
LBPH
Longboard Pharmaceuticals
1.428 of 5 stars
$18.80
-0.7%
$43.67
+132.3%
+158.8%$730.94MN/A-8.3950News Coverage
Positive News
GHRS
GH Research
2.3899 of 5 stars
$13.70
+2.8%
$36.67
+167.6%
+20.9%$712.81MN/A-22.1049Short Interest ↓
SAGE
Sage Therapeutics
4.1394 of 5 stars
$11.78
+4.1%
$37.67
+219.8%
-77.6%$708.92M$86.46M-1.40487Analyst Upgrade
News Coverage
LYEL
Lyell Immunopharma
1.4055 of 5 stars
$2.77
+2.2%
$5.50
+98.6%
-16.8%$706.18M$130,000.00-3.08224Positive News
ALXO
ALX Oncology
2.5679 of 5 stars
$13.17
-10.3%
$18.83
+43.0%
+44.0%$686.16MN/A-3.5472Analyst Forecast
Short Interest ↑

Related Companies and Tools

This page (NASDAQ:OGI) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners